Transforming Growth Factor Beta 2 - Pipeline Review, H2 2019
Transforming Growth Factor Beta 2 - Pipeline Review, H2 2019
SUMMARY
According to the recently published report 'Transforming Growth Factor Beta 2 - Pipeline Review, H2 2019'; Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.
Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Transforming growth factor beta 2 (TGF-?2) is a polypeptide member of the transforming growth factor beta superfamily of cytokines encoded by the TGFB2 gene. It regulates proliferation, differentiation, adhesion and migration. It has suppressive effects on interleukin-2 dependent T-cell growth.
The report 'Transforming Growth Factor Beta 2 - Pipeline Review, H2 2019' outlays comprehensive information on the Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 2 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Report covers products from therapy areas Oncology, Ophthalmology, Dermatology, Gastrointestinal, Genetic Disorders, Genito Urinary System And Sex Hormones, Metabolic Disorders, Musculoskeletal Disorders and Respiratory which include indications Glioblastoma Multiforme (GBM), Open-Angle Glaucoma, Age Related Macular Degeneration, Choroidal Neovascularization, Colorectal Cancer, Diabetic Macular Edema, Fibrosis, Head And Neck Cancer, High-Grade Glioma, Idiopathic Pulmonary Fibrosis, Kidney Fibrosis, Liver Fibrosis, Melanoma, Metastatic Breast Cancer, Metastatic Lung Cancer, Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Osteogenesis Imperfecta, Pancreatic Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Proliferative Vitreoretinopathy (PVR), Scar and Solid Tumor.
SCOPE
SUMMARY
According to the recently published report 'Transforming Growth Factor Beta 2 - Pipeline Review, H2 2019'; Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.
Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Transforming growth factor beta 2 (TGF-?2) is a polypeptide member of the transforming growth factor beta superfamily of cytokines encoded by the TGFB2 gene. It regulates proliferation, differentiation, adhesion and migration. It has suppressive effects on interleukin-2 dependent T-cell growth.
The report 'Transforming Growth Factor Beta 2 - Pipeline Review, H2 2019' outlays comprehensive information on the Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 2 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Report covers products from therapy areas Oncology, Ophthalmology, Dermatology, Gastrointestinal, Genetic Disorders, Genito Urinary System And Sex Hormones, Metabolic Disorders, Musculoskeletal Disorders and Respiratory which include indications Glioblastoma Multiforme (GBM), Open-Angle Glaucoma, Age Related Macular Degeneration, Choroidal Neovascularization, Colorectal Cancer, Diabetic Macular Edema, Fibrosis, Head And Neck Cancer, High-Grade Glioma, Idiopathic Pulmonary Fibrosis, Kidney Fibrosis, Liver Fibrosis, Melanoma, Metastatic Breast Cancer, Metastatic Lung Cancer, Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Osteogenesis Imperfecta, Pancreatic Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Proliferative Vitreoretinopathy (PVR), Scar and Solid Tumor.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2)
- The report reviews Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Overview
Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Companies Involved in Therapeutics Development
Avacta Life Sciences Ltd
Genzyme Corp
Isarna Therapeutics GmbH
Novartis AG
Oncotelic Inc
Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Drug Profiles
Antisense Oligonucleotide 1 to Inhibit TGFB2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVA-027 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
decorin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fresolimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISTH-0036 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISTH-0047 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LNAOT-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trabedersen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XOMA-089 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Dormant Products
Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Discontinued Products
Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Product Development Milestones
Featured News & Press Releases
Dec 02, 2019: Mateon Therapeutics team publishes three new peer-reviewed oncology articles outlining the clinical impact Potential of its first-in-class anti-TGF-beta RNA therapeutic OT101/Trabedersen
Nov 18, 2019: Mateon Therapeutics to present new and updated data for OT101 (Trabedersen) activity against brain tumors at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting
Oct 23, 2019: New research study provides target validation for Mateon's first-in-class RNA therapeutic OT101 for the treatment of difficult to treat forms of childhood brain tumor
Sep 23, 2019: FDA grants Pediatric Disease Designation for Mateons OT101
Jul 30, 2019: Oncotelic provides clinical development update on patented lead anti-cancer drug candidate OT101
Jul 16, 2019: Internationally recognized top neurosurgeon joins the Medical Advisory Board of Oncotelic
Jun 03, 2019: WideTrial partners With Oncotelic to bring expanded access platform to cancer
Mar 04, 2019: Oncotelic reports clinical validation of drug induce xenogenization (DIX) for treatment of glioblastoma and pancreatic cancer (PC)
Feb 13, 2019: Oncotelic reports that itS proprietary in-situ cancer vaccine improved survival over standard chemotherapy in patients with Recurrent Metastatic Pancreas Cancer and Recurrent High Grade Glioma
Jan 22, 2019: Oncotelic announces appointment of Fatih Uckun MD PhD to Chief Medical Officer
Dec 26, 2018: Scientists develop sight-saving treatment for eye infection
May 15, 2017: Isarna Presents Positive Clinical Data for ISTH0036 in Advanced Glaucoma and Preclinical Data Supportive of AMD/DME Potential at ARVO 2017 Annual Conference
Mar 30, 2017: Oncotelic and Autotelic to present data on OT-101 program at 2017 American Association for Cancer Research Annual Meeting
Sep 02, 2016: Oncotelic and Autotelic Announce Clinical Data Supporting IL-8 Spike as a Prognostic Biomarker for Immunotherapy
May 04, 2016: Isarna Presents First Interim Phase I Data for ISTH0036 in Advanced Glaucoma at ARVO 2016 Annual Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Overview
Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Companies Involved in Therapeutics Development
Avacta Life Sciences Ltd
Genzyme Corp
Isarna Therapeutics GmbH
Novartis AG
Oncotelic Inc
Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Drug Profiles
Antisense Oligonucleotide 1 to Inhibit TGFB2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVA-027 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
decorin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fresolimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISTH-0036 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISTH-0047 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LNAOT-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trabedersen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XOMA-089 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Dormant Products
Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Discontinued Products
Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Product Development Milestones
Featured News & Press Releases
Dec 02, 2019: Mateon Therapeutics team publishes three new peer-reviewed oncology articles outlining the clinical impact Potential of its first-in-class anti-TGF-beta RNA therapeutic OT101/Trabedersen
Nov 18, 2019: Mateon Therapeutics to present new and updated data for OT101 (Trabedersen) activity against brain tumors at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting
Oct 23, 2019: New research study provides target validation for Mateon's first-in-class RNA therapeutic OT101 for the treatment of difficult to treat forms of childhood brain tumor
Sep 23, 2019: FDA grants Pediatric Disease Designation for Mateons OT101
Jul 30, 2019: Oncotelic provides clinical development update on patented lead anti-cancer drug candidate OT101
Jul 16, 2019: Internationally recognized top neurosurgeon joins the Medical Advisory Board of Oncotelic
Jun 03, 2019: WideTrial partners With Oncotelic to bring expanded access platform to cancer
Mar 04, 2019: Oncotelic reports clinical validation of drug induce xenogenization (DIX) for treatment of glioblastoma and pancreatic cancer (PC)
Feb 13, 2019: Oncotelic reports that itS proprietary in-situ cancer vaccine improved survival over standard chemotherapy in patients with Recurrent Metastatic Pancreas Cancer and Recurrent High Grade Glioma
Jan 22, 2019: Oncotelic announces appointment of Fatih Uckun MD PhD to Chief Medical Officer
Dec 26, 2018: Scientists develop sight-saving treatment for eye infection
May 15, 2017: Isarna Presents Positive Clinical Data for ISTH0036 in Advanced Glaucoma and Preclinical Data Supportive of AMD/DME Potential at ARVO 2017 Annual Conference
Mar 30, 2017: Oncotelic and Autotelic to present data on OT-101 program at 2017 American Association for Cancer Research Annual Meeting
Sep 02, 2016: Oncotelic and Autotelic Announce Clinical Data Supporting IL-8 Spike as a Prognostic Biomarker for Immunotherapy
May 04, 2016: Isarna Presents First Interim Phase I Data for ISTH0036 in Advanced Glaucoma at ARVO 2016 Annual Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Avacta Life Sciences Ltd, H2 2019
Pipeline by Genzyme Corp, H2 2019
Pipeline by Isarna Therapeutics GmbH, H2 2019
Pipeline by Novartis AG, H2 2019
Pipeline by Oncotelic Inc, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Avacta Life Sciences Ltd, H2 2019
Pipeline by Genzyme Corp, H2 2019
Pipeline by Isarna Therapeutics GmbH, H2 2019
Pipeline by Novartis AG, H2 2019
Pipeline by Oncotelic Inc, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Avacta Life Sciences Ltd
Genzyme Corp
Isarna Therapeutics GmbH
Novartis AG
Oncotelic Inc
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Avacta Life Sciences Ltd
Genzyme Corp
Isarna Therapeutics GmbH
Novartis AG
Oncotelic Inc
